Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIJ821 single subcutaneous injection in treatment-resistant depression
2021-005992-38Phase 2Active
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in treatment-resistant depression (TRD) and major depressive disorder (MDD) comparing MIJ821 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: MADRS total score at 24 hours. Started Aug 2022; status: active.
02
Drugs
onfasprodil
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-005992-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005992-38.